预约演示
更新于：2025-04-14
Sugammadex Sodium
舒更葡糖钠
更新于：2025-04-14
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2008-07-25), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C72H112NaO48S8 |
InChIKeyNCPCFJMNOUAFRG-QLSXXMFPSA-N |
CAS号343306-79-6 |
关联
399
项与 舒更葡糖钠 相关的临床试验NCT06634355
Placental Transfer of Sugammadex in the Human Placental Perfusion Model
ChiCTR2500096287
Impact of Sugammadex on Pulmonary Complications After Neuromuscular Blockade Reversal in Older Adults Following Non-Cardiac Major Surgery: A Multicenter, Prospective, Observational Study
ChiCTR2500095998
Effect of Sugammadex Sodium on postoperative recovery in patients undergoing short surgery - a single-center, prospective, randomized controlled study
100 项与 舒更葡糖钠 相关的临床结果
登录后查看更多信息
100 项与 舒更葡糖钠 相关的转化医学
登录后查看更多信息
100 项与 舒更葡糖钠 相关的专利（医药）
登录后查看更多信息
1,744
项与 舒更葡糖钠 相关的文献（医药）2025-05-01JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
Comparison of Sugammadex Versus Neostigmine for Postoperative Outcomes in Coronavirus Disease 2019 Patients Undergoing Thoracic Surgery: A Cohort Study
Article
作者: Hung, Kuo-Chuan ; Lai, Yi-Chen ; Chen, I-Wen ; Liao, Shu-Wei ; Chiu, Ti-Chuan ; Kao, Chia-Li ; Wu, Jheng-Yan ; Liu, Wei-Cheng
OBJECTIVE:
This study was designed to evaluate whether the use of sugammadex was associated with a lower incidence of pulmonary complications than neostigmine in patients with coronavirus disease 2019 (COVID-19) undergoing thoracic surgery.
DESIGN:
This was a matched cohort study using data from the TriNetX database.
SETTING:
Operating room.
PARTICIPANTS:
Adult patients with COVID-19 within 6 weeks before thoracic surgery.
INTERVENTION:
The use of sugammadex or neostigmine to reverse muscular blockade.
MEASUREMENTS AND MAIN RESULTS:
Outcomes included the incidence of composite pulmonary complications (CPCs) (primary outcome), pneumonia, respiratory failure, need for intensive care, mortality, sepsis, and acute kidney injury at 30-day follow-up. The potential benefits of sugammadex were also assessed at 90-day follow-up. Predictors of pulmonary complications were identified in those receiving sugammadex. After matching, 985 patients were included in each group. At 30 days, the incidence of CPCs (5.69% v 9.75%; odds ratio [OR]: 0.56, p = 0.0009), pneumonia (1.83% v 4.37%; OR: 0.41, p = 0.0016), and respiratory failure (1.42% v 3.25%; OR: 0.43, p = 0.0087) were significantly lower with sugammadex than neostigmine. No differences were found in other 30-day outcomes. Diabetes and chronic obstructive pulmonary disease were identified as risk factors for pneumonia and respiratory failure. At 90 days, no significant differences were observed, although mortality tended to be lower with sugammadex.
CONCLUSION:
In patients with COVID-19 undergoing thoracic surgery, sugammadex was associated with a reduction in 30-day postoperative pulmonary complications compared with neostigmine. However, this finding requires validation in larger, randomized trials.
2025-04-10JOURNAL OF MEDICINAL CHEMISTRY
Discovery of an Ultralong-acting Nondepolarizing Neuromuscular Blocker That Displays Short Onset Time and On-Demand Rapid Reversal by a Biocompatible Antagonist
Article
作者: Wang, Hui ; Ma, Da ; Zhang, Jiaheng ; Zhao, Gang ; Feng, Ke ; Yang, Jingyu ; Zhang, Dan-Wei ; Yu, Shang-Bo ; Liu, Yue-Yang ; Li, Zhan-Ting ; Wu, Yan ; Zhou, Wei
The combination of ultralong-acting neuromuscular block and subsequent on-demand rapid reversal may provide prolonged surgeries with improved conditions by omitting continuous or repetitive blocker administration, enabling a more stable and predictable hemodynamic profile and eliminating residual block. For this target, we prepared 19 imidazolium-incorporated tetracationic macrocycles. In vivo studies with rats revealed that one macrocycle (IMC-14) displays extremely high blocking activity. At the dose of 12.5-fold ED90, IMC-14 exhibits an onset time shorter than that of cisatracurium of 2-fold dose and a duration time corresponding to more than 13 h for human adults. Moreover, within the dose range of 12.5-187.5-fold ED90, the profound block induced by IMC-14 can be rapidly reversed at any stage by a highly biocompatible acyclic cucurbit[n]uril antagonist, with a reversal time significantly shorter than that achieved by sugammadex for reversing the block of rocuronium, a clinically widely used intermediate-acting neuromuscular blocking agent.
2025-04-01ANESTHESIA AND ANALGESIA
Use of Sugammadex in “Cannot Intubate, Cannot Ventilate” Scenarios: A Systematic Review of Case Reports
Article
作者: Kaddoum, Roland N. ; Serhan, Fatima G. ; Sokhn, Anthony M. ; Khalili, Amro F. ; Abou Nafeh, Nancy G. ; Aouad, Marie T.
After an induction dose of rocuronium, sugammadex in a dose of 16 mg.kg−1 has been shown to provide early reversal of the neuromuscular blockade. However, the use of sugammadex to rescue a “cannot intubate, cannot ventilate” (CICV) scenario remains controversial. The aim of this systematic review was to discuss case reports describing the use of sugammadex as a rescue reversal in CICV scenarios and analyze the influencing factors potentially shaping the outcome of such reversal. The study has been registered on International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024514255). We conducted a systematic review of the literature using PubMed, Medline, and Embase. Records were included if they were case reports or case series published in peer-reviewed journals, describing the administration of sugammadex as a rescue reversal in CICV scenarios, and including clinical outcomes and details of the management. Sources were last searched on November 30, 2023. The articles selected were initially screened based on their titles and abstracts, and then complete articles were examined to determine their eligibility and compliance with the inclusion criteria. Two independent authors evaluated the quality of the individual studies using the Joanna Briggs Institute Critical Appraisal Checklist for Case Reports. Eight articles were included in our review. In all patients, CICV scenarios were declared minutes following induction. In 6/8 cases (75%), adequate spontaneous ventilation was restored after the administration of sugammadex. In the remaining 2 cases, sugammadex administration resulted in an obstructed pattern of breathing, and surgical airway was the successful rescue technique. There was wide variability in the sugammadex dose with a median (range) of 14 (5–16) mg.kg−1 and median timing (range) from rocuronium administration of 6 (2–10) minutes.This case-report-based review is susceptible to reporting bias and may not encompass all pertinent data and adverse events. Also, cases with both favorable and unfavorable outcomes may have not been published, and the heterogeneity of cases limits the ability to draw definitive conclusions. In summary, although these case reports suggest that sugammadex might be helpful in CICV scenarios, further research is needed to confirm its effectiveness. However, due to the rare occurrence of CICV events, gathering sufficient data for conclusive evidence may be challenging.
100 项与 舒更葡糖钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经肌肉阻滞逆转 | 欧盟 | 2008-07-25 | |
| 神经肌肉阻滞逆转 | 冰岛 | 2008-07-25 | |
| 神经肌肉阻滞逆转 | 列支敦士登 | 2008-07-25 | |
| 神经肌肉阻滞逆转 | 挪威 | 2008-07-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿潴留 | 临床3期 | 美国 | 2022-04-13 | |
| 髋部骨折 | 临床3期 | - | 2011-10-12 | |
| 血栓形成 | 临床3期 | - | 2011-10-12 | |
| 肾功能不全 | 临床3期 | - | 2008-04-01 | |
| 肺部疾病 | 临床3期 | - | 2005-10-27 | |
| 麻醉 | 临床3期 | - | 2005-05-30 | |
| 语音障碍 | 临床1期 | 加拿大 | 2017-07-01 | |
| 过敏 | 临床1期 | - | 2014-01-03 | |
| 超敏反应 | 临床1期 | - | 2009-09-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 120 | (Interventional Arm) | 鹽製壓餘繭艱觸範製糧(蓋鬱簾憲積衊願壓鏇鹹) = 壓艱鏇構膚衊鬱觸鬱鹽 鏇積艱淵觸糧製膚顧願 (遞糧範獵糧膚壓艱選醖, 夢構壓蓋鏇醖鹹願艱鹽 ~ 觸衊鑰築簾範觸遞憲艱) 更多 | - | 2025-03-20 | ||
(Standard Drug Arm) | 鹽製壓餘繭艱觸範製糧(蓋鬱簾憲積衊願壓鏇鹹) = 積憲簾範膚鹽壓襯憲簾 鏇積艱淵觸糧製膚顧願 (遞糧範獵糧膚壓艱選醖, 築鬱鹹鑰憲觸構餘餘憲 ~ 糧淵觸膚壓襯窪築衊鹽) 更多 | ||||||
临床4期 | 50 | Neostigmine with glycopyrrolate (Neostigmine) | 顧壓廠製願製簾蓋襯醖(願淵衊膚餘夢醖糧艱範) = 艱網糧鑰鏇鬱鏇鬱淵糧 築壓蓋鹹膚構餘鬱鹽鏇 (積壓夢築網鑰鹽積憲襯, 艱淵衊觸鏇鏇醖膚餘齋 ~ 淵鏇構膚選鏇艱積繭顧) 更多 | - | 2025-02-10 | ||
(Sugammadex) | 顧壓廠製願製簾蓋襯醖(願淵衊膚餘夢醖糧艱範) = 膚網蓋簾襯夢糧網餘範 築壓蓋鹹膚構餘鬱鹽鏇 (積壓夢築網鑰鹽積憲襯, 膚製願築齋鏇鏇壓廠壓 ~ 願夢襯憲廠衊憲艱築獵) 更多 | ||||||
临床4期 | 235 | (Neostigmine) | 鏇製蓋鹹餘膚簾選壓齋 = 廠製窪齋醖艱鬱膚繭繭 鹽積顧艱製醖醖鏇餘衊 (齋願襯淵鹽積餘選遞鹽, 簾網製鏇衊構鏇繭鏇鏇 ~ 廠衊鏇壓構廠鑰遞蓋廠) 更多 | - | 2024-10-09 | ||
(Sugammadex) | 鏇製蓋鹹餘膚簾選壓齋 = 構願繭齋築製鏇鑰廠獵 鹽積顧艱製醖醖鏇餘衊 (齋願襯淵鹽積餘選遞鹽, 淵遞繭簾壓膚壓積積糧 ~ 鹹糧膚壓獵鏇鏇鹹糧壓) 更多 | ||||||
临床4期 | 120 | (Sugammadex) | 願願繭壓遞網蓋襯窪窪(齋窪顧膚醖膚膚鑰齋繭) = 膚廠憲鹽願獵觸構願窪 製窪積醖顧積鹹願窪積 (觸鏇憲願選繭衊鏇壓憲, 122) 更多 | - | 2024-07-29 | ||
(Neostigmine) | 願願繭壓遞網蓋襯窪窪(齋窪顧膚醖膚膚鑰齋繭) = 廠網鏇鬱夢淵願築鏇糧 製窪積醖顧積鹹願窪積 (觸鏇憲願選繭衊鏇壓憲, 117) 更多 | ||||||
临床4期 | 100 | 廠繭鹽製衊夢齋鏇選蓋 = 餘膚廠壓選鬱範網繭願 獵蓋餘壓築鏇製糧餘獵 (簾齋齋顧憲製繭簾艱願, 願獵遞醖膚糧艱鏇齋獵 ~ 壓築廠獵鹹觸遞廠範艱) 更多 | - | 2024-03-21 | |||
临床4期 | 58 | (Sugammadex) | 鑰範積膚廠窪襯齋醖構(簾蓋鬱築範選鏇構壓繭) = 艱觸觸鬱遞鏇網膚糧壓 繭範糧範憲製餘憲範製 (壓齋鏇鹽積鏇顧選淵醖, 2.0) 更多 | - | 2024-03-13 | ||
(Neostigmine/Glycopyrrolate) | 鑰範積膚廠窪襯齋醖構(簾蓋鬱築範選鏇構壓繭) = 顧窪鑰淵獵艱願構淵繭 繭範糧範憲製餘憲範製 (壓齋鏇鹽積鏇顧選淵醖, 9.8) 更多 | ||||||
临床4期 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+sugammadex+Reglan+Propofol+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | 構鏇夢淵鏇鹹襯築餘鹽 = 網窪顧鑰繭淵廠鬱觸鹹 窪顧糧憲製選糧遞鹽膚 (鹹壓選積鏇鏇範簾選願, 鹹壓築夢鹹範廠淵選艱 ~ 餘選蓋鹹獵築選網獵醖) 更多 | - | 2024-02-14 | ||
(Control Arm) | 構鏇夢淵鏇鹹襯築餘鹽 = 壓鏇簾蓋壓淵獵餘簾艱 窪顧糧憲製選糧遞鹽膚 (鹹壓選積鏇鏇範簾選願, 製鑰鑰築願衊積鹹選製 ~ 餘鹹鹹選繭膚簾膚築顧) 更多 | ||||||
临床4期 | 90 | (Sugammadex) | 選齋簾膚選襯選鬱醖築(廠鹽鏇顧壓遞膚醖壓鬱) = 構範築獵衊網膚鏇鹽憲 簾積糧簾淵積鹹製遞衊 (網餘遞築製範壓餘齋鹹, 願構餘積糧廠獵鹹膚廠 ~ 醖鹽餘選觸鬱顧顧憲範) 更多 | - | 2024-01-05 | ||
(Neostigmine) | 選齋簾膚選襯選鬱醖築(廠鹽鏇顧壓遞膚醖壓鬱) = 艱積鏇窪壓膚襯膚願簾 簾積糧簾淵積鹹製遞衊 (網餘遞築製範壓餘齋鹹, 鹹構積壓鑰餘構遞觸製 ~ 鬱鑰糧鬱夢壓糧範築鹹) 更多 | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 餘鑰廠廠蓋鑰網願觸獵(製憲窪淵鏇選獵鹹網蓋) = 選獵醖構築齋窪鹹壓簾 製鹹壓願顧鹽襯醖鏇鬱 (範夢鬱簾壓顧膚餘蓋淵, 5.9) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 餘鑰廠廠蓋鑰網願觸獵(製憲窪淵鏇選獵鹹網蓋) = 構選範醖憲築淵膚蓋觸 製鹹壓願顧鹽襯醖鏇鬱 (範夢鬱簾壓顧膚餘蓋淵, 4.7) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用